
Sino Biopharmaceutical
(OTC) SBHMY
Sino Biopharmaceutical Financials at a Glance
Market Cap
$11.31B
Revenue (TTM)
CN¥30.57B
Net Income (TTM)
CN¥3.87B
EPS (TTM)
$0.35
P/E Ratio
35.73
Dividend
$0.26
Beta (Volatility)
0.05 (Low)
Dividend
$0.26
Beta (Volatility)
0.05 (Low)
Price
$12.55
Volume
21
Open
$12.55
Price
$12.55
Volume
21
Open
$12.55
Previous Close
$12.55
Daily Range
$12.55 - $12.55
52-Week Range
$11.27 - $20.16
Estimated Earnings Date
Mar 18, 2026
Dividend
$0.26
Beta (Volatility)
0.05 (Low)
Price
$12.55
Volume
21
Open
$12.55
Previous Close
$12.55
Daily Range
$12.55 - $12.55
52-Week Range
$11.27 - $20.16
Estimated Earnings Date
Mar 18, 2026
SBHMY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sino Biopharmaceutical
Industry
Pharmaceuticals
Sector
Health CareEmployees
21,435
CEO
S Y Tse
Website
www.sinobiopharm.comHeadquarters
Wan Chai, HK
SBHMY Financials
Key Financial Metrics (TTM)
Gross Margin
82.07%
Operating Margin
21.84%
Net Income Margin
7.36%
Return on Equity
7.22%
Return on Capital
14.17%
Return on Assets
3.08%
Earnings Yield
2.80%
Dividend Yield
2.02%
Payout Ratio
0.00%
Stock Overview
Market Cap
$11.31B
Shares Outstanding
891.82M
Volume
21
Avg. Volume
23.436
Financials (TTM)
Gross Profit
CN¥24.99B
Operating Income
CN¥6.15B
EBITDA
CN¥6.13B
Operating Cash Flow
CN¥3.16B
Capital Expenditure
-CN¥270.85M
Free Cash Flow
CN¥2.89B
Cash & ST Invst.
CN¥22.96B
Total Debt
CN¥16.07B
Sino Biopharmaceutical Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
CN¥8.79B
+10.7%
Gross Profit
CN¥7.25B
+11.2%
Gross Margin
82.47%
N/A
Market Cap
$11.31B
N/A
Market Cap/Employee
$463.85K
N/A
Employees
24,379
N/A
Net Income
CN¥1.69B
+12.3%
EBITDA
CN¥1.98B
+0.1%
Quarterly Fundamentals
Total Cash
CN¥22.96B
+57.3%
Total Debt
CN¥16.07B
+64.3%
Accounts Receivable
CN¥7.87B
+58.4%
Inventory
CN¥2.26B
-4.9%
Long Term Debt
CN¥7.65B
+267.8%
Short Term Debt
CN¥8.42B
+9.3%
Return on Assets
3.08%
N/A
Return on Invested Capital
13.69%
N/A
Free Cash Flow
CN¥1.44B
+8.2%
Operating Cash Flow
CN¥1.58B
+2.7%